Adult Child & Adolescent Psychiatric Services
ACAPS will be closed on Thursday, November 28, and Friday, November 29, in observance of Thanksgiving. We will resume regular hours on Monday, December 2. Have a safe and happy holiday!
SPRAVATO Treatment
What Is SPRAVATO® (esketamine)?
SPRAVATO™ nasal spray is a different kind of medication taken with an oral antidepressant for adults with treatment-resistant depression – a first in decades approved by the FDA.
What are the uses of SPRAVATO™ ?
SPRAVATO™ is used to treat adults with treatment-resistant depression.
Is SPRAVATO™ FDA Approved
Yes. On March 5, 2019, esketamine CIII nasal spray (Spravato; Janssen Pharmaceuticals) was approved by the US Food and Drug Administration (FDA), in conjunction with an oral antidepressant, for the treatment of adults with treatment-resistant depression.
SPRAVATO™ Treatment at ACAPS
- You will take SPRAVATO® nasal spray yourself, under the supervision ACAPS provider in one of our clinical setting. Your provider will show you how to use the SPRAVATO® nasal spray device.
- ACAPS healthcare provider will tell you how much SPRAVATO® you will take and when you will take it.
- Follow your SPRAVATO® treatment schedule exactly as your healthcare provider tells you to.
- During and after each use of the SPRAVATO® nasal spray device, you will be checked by ACAPS healthcare provider who will decide when you are ready to leave the healthcare setting.
- You will need to plan for a caregiver or family member to drive you home after taking SPRAVATO®.
- If you miss a SPRAVATO® treatment, your healthcare provider may change your dose and treatment schedule.
- Some people taking SPRAVATO® get nausea and vomiting. You should not eat for at least 2 hours before taking SPRAVATO® and not drink liquids at least 30 minutes before taking SPRAVATO®.
- If you take a nasal corticosteroid or nasal decongestant medicine take these medicines at least 1 hour before taking SPRAVATO®.